Chronic lung disease in survivors · neonates with sepsis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean daily rating of problem severity (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Mean change in daily rating of functional impairment: reduction of productivity (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Mean change in daily rating of functional impairment: social activities (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Mean change in daily rating of functional impairment: relationship interference (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Changes in Premenstrual Tension Scale scores (observer‐rated; lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Changes in Premenstrual Tension Scale scores (self‐rated; lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Withdrawals due to adverse events · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
Drospirenone plus ethinylestradiol may leads to higher withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Efficacy as a continuous outcome · patients with cancer and depression
1 finding from 1 review
Efficacy as a dichotomous outcome · patients with cancer and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes efficacy as a dichotomous outcome compared with tricyclic antidepressants (TCAs) (very low certainty).
1 finding from 1 review
Acceptability ‐ total dropouts · patients with cancer and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes dropouts due to any cause (acceptability) compared with tricyclic antidepressants (TCAs) (very low certainty).
1 finding from 1 review
Efficacy as a continuous outcome · adults with cancer and depression
1 finding from 1 review
Efficacy as a dichotomous outcome · adults with cancer and depression
It is very uncertain whether mirtazapine changes efficacy as a dichotomous outcome compared with tricyclic antidepressants (TCA) (very low certainty).
1 finding from 1 review
Acceptability ‐ total dropouts · adults with cancer and depression
It is very uncertain whether mirtazapine changes dropouts due to any cause (acceptability) compared with tricyclic antidepressants (TCA) (very low certainty).
1 finding from 1 review
UGIH‐related mortality · people with acute UGIH
1 finding from 1 review
SAEs · people with acute UGIH
1 finding from 1 review
All‐cause mortality · people with acute UGIH
It is very uncertain whether erythromycin changes all‐cause mortality compared with nasogastric tube lavage (very low certainty).
1 finding from 1 review
NSAEs · people with acute UGIH
It is very uncertain whether erythromycin changes NSAEs compared with nasogastric tube lavage (very low certainty).
1 finding from 1 review
Rebleeding · people with acute UGIH
It is very uncertain whether erythromycin changes rebleeding compared with nasogastric tube lavage (very low certainty).
1 finding from 1 review
Blood transfusion · people with acute UGIH
1 finding from 1 review